# Your first week on semaglutide: what to expect Canonical page: https://bodienvi.com/blog/first-week-on-semaglutide-guide Published September 22, 2026. Updated September 22, 2026. By Bodi Envi Clinical Content Team. What the Wegovy® label says about the starting dose and early effects, how to check and store a compounded vial, and when to message your care team. ## Before the first dose The first week on semaglutide is mostly logistics: the medication arrives, you check it, you store it, you work out how to measure and inject it, and you take the first dose. This guide walks through that week using what the FDA-approved Wegovy® label says about the starting dose, early side effects, storage and administration, and what the FDA says about compounded products on arrival. It ends with the moments when a message to your care team is the right move. This is general information and not medical advice. The label describes Wegovy®, the branded product. Personalized Compounded semaglutide, which Bodi Envi's programs may include, is not FDA-approved, was not studied in the label's trials and is not equivalent to the approved product. Your provider sets your plan and your pharmacy label gives the instructions for your vial; both override anything general here. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## What the label says about the start The Wegovy® label describes a starting dose of 0.25 mg injected under the skin once weekly for the first four weeks, followed by increases at four week intervals. It states the reason plainly: the escalation exists to reduce the risk of gastrointestinal adverse reactions. The label's pharmacokinetics explain the pace. Semaglutide has a half-life of about a week, so the level in the body builds over several weeks on each dose rather than arriving all at once. The first injection is a small fraction of the maintenance dose, and the first week is the lowest exposure of the whole course. That is a description of the approved product. With a compounded prescription, your provider sets your starting dose and the timing of any change, and the guide on this site to the label schedule explains how a compounded vial is measured differently. The number your provider gives you is in milligrams; the number on your syringe depends on the concentration printed on your pharmacy label, and that label is the only correct conversion for your vial. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## What the label says you might notice with the brand name product The label reports nausea in 44 percent of adults on the 2.4 mg maintenance dose over 68 weeks, diarrhea in 30 percent, and vomiting and constipation in 24 percent each, with the escalation schedule designed to limit them. The STEP 1 trial, published in the New England Journal of Medicine in 2021, describes the nausea and diarrhea seen as typically transient and mild to moderate, subsiding with time. This was a study on the brand name version, not the personalized compounded product. This is for educational purposes only and is not intended to compare a personalized compounded product to the brand. What that means for week one is limited. The figures cover the whole course at the full dose, not the first week at the starting dose, and they are averages across thousands of people. Some people notice reduced appetite or mild nausea after the first injection and some notice nothing. This guide does not predict which you will be, and it does not state an outcome for anyone. What it can say is that the label's design assumes the early weeks are when the body adjusts, and that the label's tools for a dose that is not tolerated, delaying the next step by four weeks and weighing tolerability in the maintenance dose, are there for a reason. The nausea guide on this site goes into what the label and published sources support for the most common effect. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## What to check when it arrives The FDA's statement on unapproved GLP-1 drugs, dated September 1, 2026, gives the arrival checklist for a compounded product. Injectable GLP-1 drugs require refrigeration, and the agency has received complaints of compounded products arriving warm or with inadequate ice packs; it recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration. It lists among the warning signs of an unsafe product one that arrives in packaging that is broken or damaged or lacks instructions for use, one whose label has spelling errors or an incorrect pharmacy address, and one that looks different from what was pictured or previously received. So, on arrival: confirm the package is cold. Confirm the pharmacy label carries your name, the pharmacy's name and contact details, the medication and its concentration, and instructions for use. Look at the solution; the Wegovy® label says to use the medication only if it is clear, colorless and contains no particles, and the same standard is the sensible one for a vial. If anything is off, contact the pharmacy before using it. Bodi Envi's refund policy asks patients with a dispensing concern to contact the dispensing pharmacy promptly after delivery, using the contact details on the prescription label, and its shipping policy directs claims for packages damaged in transit to the carrier, with the packaging kept. ## Storing it The storage instructions that govern your vial are on the pharmacy label. The Wegovy® label is a reference for what the molecule needs: store the pen in the refrigerator between 36°F and 46°F, not in the freezer and not directly against the refrigerator's cooling element, protected from light and kept in its carton, and never used if it has been frozen. The label allows the branded pen a limited period at room temperature before its cap is removed, but that allowance is for the branded pen and its packaging, and it should not be assumed for a vial; the pharmacy label says what your product allows. The FDA adds one rule for compounded vials that hold more than one dose: discard the vial 28 days after first use, even if medication remains and even if the compounder's instructions say it can be used longer, because of the increased risk of contamination after that point. The storage guide on this site covers refrigeration and handling in more depth. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## Measuring and injecting The Wegovy® label describes the injection as subcutaneous, into the fatty tissue under the skin of the abdomen, thigh or upper arm, once weekly on one fixed weekday, at any time of day, with or without meals, and with the injection site rotated. It directs that patients be trained on the specific presentation they receive before the first injection, that the medication be inspected before each use, and that a new needle be used each time. For a compounded vial, the pharmacy's instructions on drawing up the dose are the ones to follow, and the FDA's warning is the reason to follow them exactly. Its statement reports adverse events, some requiring hospitalization, linked to patients measuring and self-administering incorrect doses of personalized compounded semaglutide, and asks patients to talk with their provider or compounder about how to measure and administer the intended dose. It also says to use a new sterile needle and syringe for every dose, because reuse can contaminate the medication. If anything about the measuring is unclear, the right time to ask your care team is before the first injection, not after. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## Missed or mistimed doses The label's missed dose guidance for the injection: if one dose is missed and the next scheduled dose is more than two days away, take the missed dose as soon as possible; if the next dose is less than two days away, skip the missed dose and resume on the regular day. If two or more consecutive doses are missed, escalation restarts at a lower dose. Those rules describe the branded product; for a compounded prescription, ask your care team rather than applying them yourself, because your provider's plan may differ. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## When to message your care team Bodi Envi's programs include messaging with your care team through the patient portal, and the first week is when it earns its place. Message before your first injection if anything about measuring, injecting or storing is unclear. Message if the medication arrived warm, damaged or looking wrong, after contacting the pharmacy. Message if you miss a dose, if side effects are persistent, or if you start or stop any other medication. And read the label's list of symptoms that need urgent attention, which the side effects guide on this site reproduces: severe abdominal pain that does not go away, symptoms of a serious allergic reaction, a lump or swelling in the neck, and persistent vomiting or diarrhea with signs of dehydration. Seek emergency care for anything severe. Bodi Envi is a LegitScript-certified U.S. telehealth platform and not a medical practice, pharmacy or medication manufacturer. Clinical services for applicable programs are provided by Wasef Health, PC, and a licensed provider makes every clinical decision. Personalized Compounded semaglutide is not FDA-approved and is not equivalent to Wegovy®. This is general information and not medical advice, and your provider is the person to ask. ## Frequently asked questions ### What dose does treatment start at? The Wegovy® label describes a starting dose of 0.25 mg once weekly for the first four weeks, and says the low start exists to reduce the risk of gastrointestinal side effects. With a compounded prescription your provider sets your starting dose, and the pharmacy label gives the measuring instructions for your vial. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### Will I feel anything in the first week? The label reports nausea, diarrhea, vomiting and constipation as the most common side effects and says its escalation schedule is designed to limit them, and the STEP 1 trial's authors describe early nausea as typically transient and mild to moderate. What any one person notices in week one varies, and this guide does not predict it. This is according to a brand name study; a personalized compounded product cannot be compared to the brand name product, and side effects may differ. This is for educational purposes only. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### What should I check when the medication arrives? That it is cold, that the label carries your name, the pharmacy's name and contact details, the concentration and the instructions, and that the solution is clear. The FDA advises not to use any injectable GLP-1 drug that arrives warm, and the Wegovy® label says to use the medication only if it is clear, colorless and free of particles. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### How do I store it? Follow the pharmacy label. For reference, the Wegovy® label says to store the pen in the refrigerator between 36°F and 46°F, not in the freezer or against the cooling element, protected from light and in its carton, and never to use it if it has been frozen. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### Where and how is it injected? The Wegovy® label describes a subcutaneous injection in the abdomen, thigh or upper arm, on one fixed weekday, at any time of day, with or without meals, with a new needle each time. For a compounded vial, the pharmacy's instructions on drawing up the dose apply, and your care team can answer questions before your first injection. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### When should I message my care team? Before your first injection if anything about measuring is unclear, if the medication arrived warm or looks wrong, if you miss a dose, if side effects are persistent or severe, and if you start or stop any other medication. Seek emergency care for anything severe. ## Sources - Wegovy® (semaglutide) injection prescribing information, DailyMed, revised June 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (checked September 2026) - Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021, PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/ (checked September 2026) - FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, dated September 1, 2026: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (checked September 2026) - Bodi Envi refund policy: https://bodienvi.com/refund-policy (checked September 2026) - Bodi Envi shipping policy: https://bodienvi.com/shipping-policy (checked September 2026)